Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer.
TMPRSS2:ERG
diagnosis
gene fusion
microUS
mpMRI
prostate cancer
translocation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
06
2022
accepted:
12
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
To test the hypothesis of a relationship between a specific genetic lesion (T2:ERG) and imaging scores, such as PI-RADS and PRI-MUS, and to test the effectiveness of these parameters for the diagnosis of prostate cancer (PCa) and clinically significant PCa (csPCa). This is a prospective study of men with suspected PCa enrolled between 2016 and 2019 at a high-volume tertiary hospital. Patients underwent systematic US-guided biopsy, plus targeted biopsy if they were presenting with >=1 suspicious lesion (PI-RADS>2) at mpMRI or PR-IMUS >2 at micro-ultrasound assessment. For each patient, one core from the highest PI-RADS or PRI-MUS lesion was collected for T2:ERG analysis. Multivariable logistic regression models (LRMs) were fitted for csPCa with a clinical model (age, total PSA, previous biopsy, family history for PCa), a clinical plus PI-RADS, clinical plus T2:ERG, clinical plus PI-RADS plus T2:ERG, and T2:ERG plus PI-RADS alone. The cohort consists of 158 patients: 83.5% and 66.2% had respectively a diagnosis of PCa and csPCa after biopsy. A T2:ERG fusion was found in 37 men and 97.3% of these patients harbored PCa, while 81.1% were diagnosed with csPCa. SE of T2:ERG assay for csPCa was 28.8%, SP 87.0%, NPV 38.8%, and PPV 81.1%. Of 105 patients who performed mpMRI 93.% had PIRADS ≥3. SE of mpMRI for csPCa was 98.5%, SP was 12.8%, NPV was 83.3%, and PPV was 65.7%. Among 67 patients who were subjected to micro-US, 90% had a PRI-MUS ≥3. SE of micro-US for csPCa was 89.1%, SP was 9.52%, NPV was 28.6%, and PPV was 68.3%. At univariable LRM T2:ERG was confirmed as independent of mpMRI and micro-US result (OR 1.49, p=0.133 and OR 1.82, p=0.592, respectively). At multivariable LRM the clinical model alone had an AUC for csPCa of 0.74 while the clinical model including PI-RADS and T2:ERG achieved an AUC of 0.83. T2:ERG translocation and imaging results are independent of each other, but both are related csPCa. To evaluate the best diagnostic work-up for PCa and csPCa detection, all available tools (T2:ERG detection and imaging techniques) should be employed together as they appear to have a complementary role.
Identifiants
pubmed: 36147926
doi: 10.3389/fonc.2022.968384
pmc: PMC9487838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
968384Informations de copyright
Copyright © 2022 Lazzeri, Fasulo, Lughezzani, Benetti, Soldà, Asselta, De Simone, Paciotti, Avolio, Contieri, Saitta, Saita, Hurle, Guazzoni, Buffi and Casale.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Urol Oncol. 2021 Jan 19;:
pubmed: 33483265
Cent European J Urol. 2018;71(4):410-419
pubmed: 30680235
Eur Urol Oncol. 2019 May;2(3):329-332
pubmed: 31200848
J Clin Oncol. 2014 Jan 20;32(3):206-11
pubmed: 24297949
Eur Urol. 2019 Sep;76(3):268-272
pubmed: 31128968
Clin Genitourin Cancer. 2016 Apr;14(2):117-21
pubmed: 26774207
J Urol. 2021 Feb;205(2):452-460
pubmed: 32897802
Asian J Androl. 2020 Mar-Apr;22(2):200-207
pubmed: 31210145
J Urol. 2020 Dec;204(6):1222-1228
pubmed: 33157570
Lancet Oncol. 2021 Nov;22(11):1618-1631
pubmed: 34678156
Eur Urol. 2013 Jun;63(6):986-94
pubmed: 23375961
Urol Oncol. 2013 Jul;31(5):566-71
pubmed: 21600800
Eur Urol. 2015 Jun;67(6):1112-1121
pubmed: 25466942
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Curr Oncol Rep. 2016 May;18(5):30
pubmed: 27023445
Sci Transl Med. 2012 Mar 28;4(127):127rv3
pubmed: 22461644
Eur Urol. 2022 Feb;81(2):216-218
pubmed: 34895922
Neoplasia. 2006 Oct;8(10):885-8
pubmed: 17059688
Clin Transl Oncol. 2021 Jan;23(1):172-178
pubmed: 32447644
Clin Cancer Res. 2009 Jul 15;15(14):4706-11
pubmed: 19584163
Oncogene. 2005 May 26;24(23):3847-52
pubmed: 15750627
J Urol. 2011 Oct;186(4):1281-5
pubmed: 21849184
J Urol. 2016 Aug;196(2):562-9
pubmed: 26791931
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986955
JAMA. 1993 Aug 25;270(8):948-54
pubmed: 7688438
Am J Surg Pathol. 2007 Jun;31(6):882-8
pubmed: 17527075
JAMA Oncol. 2017 Aug 01;3(8):1085-1093
pubmed: 28520829
Cancers (Basel). 2022 Feb 22;14(5):
pubmed: 35267426
Clin Chem. 2013 Jan;59(1):280-8
pubmed: 23213079
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):370-5
pubmed: 26345389
J Urol. 2018 Jul;200(1):95-103
pubmed: 29409824
Am J Epidemiol. 2017 Dec 15;186(12):1352-1361
pubmed: 28633309
Oncotarget. 2020 Apr 14;11(15):1321-1333
pubmed: 32341752
Curr Opin Urol. 2008 Jan;18(1):71-7
pubmed: 18090494
Minerva Urol Nefrol. 2019 Jun;71(3):273-279
pubmed: 30700081
Eur Urol Focus. 2021 May;7(3):546-553
pubmed: 32451315
Eur Urol Focus. 2021 Sep;7(5):1019-1026
pubmed: 33069624
J Urol. 2022 Feb;207(2):262-264
pubmed: 34775795
Clin Cancer Res. 2007 Sep 1;13(17):5103-8
pubmed: 17785564
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Eur Urol Focus. 2021 Jul;7(4):764-771
pubmed: 32312701